Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu

Joan Tymon‐Rosario, Eric R. Siegel, Stefania Bellone, Justin Harold, Naomi Adjei, Burak Zeybek, Dennis Mauricio, Gary Altwerger, Gulden Menderes, Elena Ratner, Mitchell Clark, Vaagn Andikyan, Gloria S. Huang, Masoud Azodi, Peter E. Schwartz, Amanda N. Fader, Alessandro D. Santin